We partner with Financial Exchange Radio to produce a weekly segment with Seeking Alpha authors.
Joe McCann continues the series with his bullish pick: FibroGen.
FibroGen's lead drug is roxadustat for anemia in patients with chronic kidney disease. There will be a large study on how the drug impacts patients' cardiac risk vs. the current standard of care, called a MACE analysis, sometime in the next 2 months.
I've spoken to a number of experts who gave clear reasons and opinions that roxa is likely to be as safe or better on cardiovascular events compared to EPO. If superior to EPO, it would result in significant upside for the shares.